BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18581485)

  • 21. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation.
    Crippin JS; McCashland T; Terrault N; Sheiner P; Charlton MR
    Liver Transpl; 2002 Apr; 8(4):350-5. PubMed ID: 11965579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
    Gopal DV; Rabkin JM; Berk BS; Corless CL; Chou S; Olyaei A; Orloff SL; Rosen HR
    Liver Transpl; 2001 Mar; 7(3):181-90. PubMed ID: 11244158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.
    Bizollon T; Ducerf C; Trépo C
    J Hepatol; 1995; 23 Suppl 2():22-5. PubMed ID: 8720290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
    Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
    Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
    Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
    Merli M; Giannelli V; Gentili F; Giusto M; Simmaco M; Lionetto L; Corradini SG; Biliotti E; Attili AF; Rossi M; Taliani G
    Antivir Ther; 2011; 16(6):879-85. PubMed ID: 21900720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Declining sustained virological response in hepatitis C.
    Batool U; Qureshi S
    J Coll Physicians Surg Pak; 2006 Mar; 16(3):187-91. PubMed ID: 16542597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double Filtration Plasmapheresis in Treatment of Patients With Co-Infection of Hepatitis C and Human Immunodeficiency Virus.
    Mednikov RV; Rabinovich VI; Kizlo SN; Belyakov NA; Sokolov AA
    Ther Apher Dial; 2016 Aug; 20(4):413-9. PubMed ID: 27059644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin.
    Götz G; Schön MR; Haefker A; Neuhaus R; Berg T; Hopf U; Neuhaus P
    Transplant Proc; 1998 Aug; 30(5):2104-6. PubMed ID: 9723407
    [No Abstract]   [Full Text] [Related]  

  • 39. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study.
    Yamashita T; Arai K; Sakai A; Mizukoshi E; Sakai Y; Kagaya T; Nakamoto Y; Honda M; Wada T; Yokoyama H; Kaneko S
    Hepatol Res; 2006 Nov; 36(3):167-75. PubMed ID: 16959538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Living donor liver transplantation for patients with hepatitis C virus cirrhosis: Tokyo experience.
    Sugawara Y; Makuuchi M
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S122-4. PubMed ID: 16234059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.